Form 3 MapLight Therapeutics, For: Oct 25 Filed by: Kreitzer Anatol
MapLight Therapeutics, Inc. (MPLT)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
MPLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MPLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MPLT alerts
High impacting MapLight Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MPLT
News
- MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate ProgressGlobeNewswire
- Maplight Therapeutics (NASDAQ:MPLT) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.MarketBeat
- Maplight Therapeutics (NASDAQ:MPLT) was upgraded by analysts at Zacks Research to a "hold" rating.MarketBeat
- Maplight Therapeutics (NASDAQ:MPLT) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Maplight Therapeutics (NASDAQ:MPLT) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MPLT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall SMarketBeat
MPLT
Sec Filings
- 12/4/25 - Form 10-Q
- 12/4/25 - Form 8-K
- 11/20/25 - Form SCHEDULE
- MPLT's page on the SEC website